J Clin Oncol:供体来源CD7嵌合抗原受体T细胞治疗急性T淋巴细胞白血病的未来可期!

2021-08-02 MedSci原创 MedSci原创

供体来源的CD7 CAR T 细胞在复发性或难治性急性T淋巴细胞白血病患者中表现出有效的扩增,并实现了很高的完全缓解率和可控的安全性

急性T淋巴细胞白血病 (T-ALL)是一种侵袭性血液恶性肿瘤,占儿童急性淋巴细胞白血病(ALL)病例的10%-15%和成人ALL病例的20%。复发性或难治性T-ALL (r/r T-ALL) 患者的治疗选择很少,而且预后较差。

本研究目的是评估患者来源的抗CD7嵌合抗原受体(CAR)T细胞用于 r/r T-ALL患者的疗效和安全性。

Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial

这是一项单中心的1期试验,以5×105 /kg或1×106 /kg(±30%)的剂量向 r/r T-ALL患者输注CD7 CAR T细胞。主要终点是安全性,次要终点是疗效。

共20位患者接受了CAR T细胞输注。不良反应事件包括细胞因子释放综合征(1-2级:90%;3-4级:10%)、3-4级的血细胞减少症(100%)、1-2级的神经毒性(15%)、1-2级的移植物抗宿主病(60%)和1-2级的病毒激活(20%)。除了一名患者死于与真菌性肺炎相关的肺出血 (发生在CAR T细胞输注后 5.5 个月),所有不良事件都是可逆的

临床缓解情况

90%的患者获得了完全缓解,7位患者进行了干细胞移植。中位随访6.3个月时,有15位患者仍处于缓解期。在输注后6个月时,对5位患者进行了检测,发现这5位患者均还可检测到CAR T细胞。

虽然患者的CD7阳性正常T细胞被耗尽,但CD7阴性T细胞扩增并可能减轻了与治疗相关的T细胞免疫缺陷。

综上所述,在参加该试验的20位 r/r T-ALL 患者中,供体来源的CD7 CAR T 细胞表现出有效的扩增,并实现了很高的完全缓解率和可控的安全性。

原始出处:

Jing Pan, et al. Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial. Journal of Clinical Oncology. July 29, 2021. https://ascopubs.org/doi/full/10.1200/JCO.21.00389

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (14)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1967941, encodeId=e941196e9415e, content=<a href='/topic/show?id=6e301800534' target=_blank style='color:#2F92EE;'>#T淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18005, encryptionId=6e301800534, topicName=T淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Thu Jun 16 16:48:07 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866177, encodeId=0e4418661e7d7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Mar 02 04:48:07 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743714, encodeId=027e1e43714c0, content=<a href='/topic/show?id=746a4e829ed' target=_blank style='color:#2F92EE;'>#嵌合抗原受体T细胞治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47829, encryptionId=746a4e829ed, topicName=嵌合抗原受体T细胞治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3baf35196076, createdName=yyanpro@33cn.c, createdTime=Wed Aug 18 01:48:07 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631896, encodeId=b4ba1631896d5, content=<a href='/topic/show?id=bd782682e3a' target=_blank style='color:#2F92EE;'>#供体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26827, encryptionId=bd782682e3a, topicName=供体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ed21829086, createdName=feather85, createdTime=Thu Jun 30 18:48:07 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998017, encodeId=ba7c199801ea9, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Thu Jan 06 11:48:07 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302392, encodeId=f922130239239, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Wed Aug 04 12:48:07 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602917, encodeId=7aa3160291e91, content=<a href='/topic/show?id=e0ee180038f' target=_blank style='color:#2F92EE;'>#T淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18003, encryptionId=e0ee180038f, topicName=T淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af0c18977520, createdName=zhenjiu129, createdTime=Wed Aug 04 12:48:07 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623400, encodeId=de111623400f3, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Wed Aug 04 12:48:07 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626746, encodeId=931e1626e46d6, content=<a href='/topic/show?id=2b104e82656' target=_blank style='color:#2F92EE;'>#嵌合抗原受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47826, encryptionId=2b104e82656, topicName=嵌合抗原受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77a421060517, createdName=dangious, createdTime=Wed Aug 04 12:48:07 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004989, encodeId=ce2210049895c, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Aug 03 22:11:11 CST 2021, time=2021-08-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1967941, encodeId=e941196e9415e, content=<a href='/topic/show?id=6e301800534' target=_blank style='color:#2F92EE;'>#T淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18005, encryptionId=6e301800534, topicName=T淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Thu Jun 16 16:48:07 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866177, encodeId=0e4418661e7d7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Mar 02 04:48:07 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743714, encodeId=027e1e43714c0, content=<a href='/topic/show?id=746a4e829ed' target=_blank style='color:#2F92EE;'>#嵌合抗原受体T细胞治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47829, encryptionId=746a4e829ed, topicName=嵌合抗原受体T细胞治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3baf35196076, createdName=yyanpro@33cn.c, createdTime=Wed Aug 18 01:48:07 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631896, encodeId=b4ba1631896d5, content=<a href='/topic/show?id=bd782682e3a' target=_blank style='color:#2F92EE;'>#供体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26827, encryptionId=bd782682e3a, topicName=供体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ed21829086, createdName=feather85, createdTime=Thu Jun 30 18:48:07 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998017, encodeId=ba7c199801ea9, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Thu Jan 06 11:48:07 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302392, encodeId=f922130239239, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Wed Aug 04 12:48:07 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602917, encodeId=7aa3160291e91, content=<a href='/topic/show?id=e0ee180038f' target=_blank style='color:#2F92EE;'>#T淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18003, encryptionId=e0ee180038f, topicName=T淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af0c18977520, createdName=zhenjiu129, createdTime=Wed Aug 04 12:48:07 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623400, encodeId=de111623400f3, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Wed Aug 04 12:48:07 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626746, encodeId=931e1626e46d6, content=<a href='/topic/show?id=2b104e82656' target=_blank style='color:#2F92EE;'>#嵌合抗原受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47826, encryptionId=2b104e82656, topicName=嵌合抗原受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77a421060517, createdName=dangious, createdTime=Wed Aug 04 12:48:07 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004989, encodeId=ce2210049895c, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Aug 03 22:11:11 CST 2021, time=2021-08-03, status=1, ipAttribution=)]
    2022-03-02 minlingfeng
  3. [GetPortalCommentsPageByObjectIdResponse(id=1967941, encodeId=e941196e9415e, content=<a href='/topic/show?id=6e301800534' target=_blank style='color:#2F92EE;'>#T淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18005, encryptionId=6e301800534, topicName=T淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Thu Jun 16 16:48:07 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866177, encodeId=0e4418661e7d7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Mar 02 04:48:07 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743714, encodeId=027e1e43714c0, content=<a href='/topic/show?id=746a4e829ed' target=_blank style='color:#2F92EE;'>#嵌合抗原受体T细胞治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47829, encryptionId=746a4e829ed, topicName=嵌合抗原受体T细胞治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3baf35196076, createdName=yyanpro@33cn.c, createdTime=Wed Aug 18 01:48:07 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631896, encodeId=b4ba1631896d5, content=<a href='/topic/show?id=bd782682e3a' target=_blank style='color:#2F92EE;'>#供体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26827, encryptionId=bd782682e3a, topicName=供体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ed21829086, createdName=feather85, createdTime=Thu Jun 30 18:48:07 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998017, encodeId=ba7c199801ea9, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Thu Jan 06 11:48:07 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302392, encodeId=f922130239239, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Wed Aug 04 12:48:07 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602917, encodeId=7aa3160291e91, content=<a href='/topic/show?id=e0ee180038f' target=_blank style='color:#2F92EE;'>#T淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18003, encryptionId=e0ee180038f, topicName=T淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af0c18977520, createdName=zhenjiu129, createdTime=Wed Aug 04 12:48:07 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623400, encodeId=de111623400f3, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Wed Aug 04 12:48:07 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626746, encodeId=931e1626e46d6, content=<a href='/topic/show?id=2b104e82656' target=_blank style='color:#2F92EE;'>#嵌合抗原受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47826, encryptionId=2b104e82656, topicName=嵌合抗原受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77a421060517, createdName=dangious, createdTime=Wed Aug 04 12:48:07 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004989, encodeId=ce2210049895c, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Aug 03 22:11:11 CST 2021, time=2021-08-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1967941, encodeId=e941196e9415e, content=<a href='/topic/show?id=6e301800534' target=_blank style='color:#2F92EE;'>#T淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18005, encryptionId=6e301800534, topicName=T淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Thu Jun 16 16:48:07 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866177, encodeId=0e4418661e7d7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Mar 02 04:48:07 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743714, encodeId=027e1e43714c0, content=<a href='/topic/show?id=746a4e829ed' target=_blank style='color:#2F92EE;'>#嵌合抗原受体T细胞治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47829, encryptionId=746a4e829ed, topicName=嵌合抗原受体T细胞治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3baf35196076, createdName=yyanpro@33cn.c, createdTime=Wed Aug 18 01:48:07 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631896, encodeId=b4ba1631896d5, content=<a href='/topic/show?id=bd782682e3a' target=_blank style='color:#2F92EE;'>#供体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26827, encryptionId=bd782682e3a, topicName=供体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ed21829086, createdName=feather85, createdTime=Thu Jun 30 18:48:07 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998017, encodeId=ba7c199801ea9, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Thu Jan 06 11:48:07 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302392, encodeId=f922130239239, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Wed Aug 04 12:48:07 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602917, encodeId=7aa3160291e91, content=<a href='/topic/show?id=e0ee180038f' target=_blank style='color:#2F92EE;'>#T淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18003, encryptionId=e0ee180038f, topicName=T淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af0c18977520, createdName=zhenjiu129, createdTime=Wed Aug 04 12:48:07 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623400, encodeId=de111623400f3, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Wed Aug 04 12:48:07 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626746, encodeId=931e1626e46d6, content=<a href='/topic/show?id=2b104e82656' target=_blank style='color:#2F92EE;'>#嵌合抗原受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47826, encryptionId=2b104e82656, topicName=嵌合抗原受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77a421060517, createdName=dangious, createdTime=Wed Aug 04 12:48:07 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004989, encodeId=ce2210049895c, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Aug 03 22:11:11 CST 2021, time=2021-08-03, status=1, ipAttribution=)]
    2022-06-30 feather85
  5. [GetPortalCommentsPageByObjectIdResponse(id=1967941, encodeId=e941196e9415e, content=<a href='/topic/show?id=6e301800534' target=_blank style='color:#2F92EE;'>#T淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18005, encryptionId=6e301800534, topicName=T淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Thu Jun 16 16:48:07 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866177, encodeId=0e4418661e7d7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Mar 02 04:48:07 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743714, encodeId=027e1e43714c0, content=<a href='/topic/show?id=746a4e829ed' target=_blank style='color:#2F92EE;'>#嵌合抗原受体T细胞治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47829, encryptionId=746a4e829ed, topicName=嵌合抗原受体T细胞治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3baf35196076, createdName=yyanpro@33cn.c, createdTime=Wed Aug 18 01:48:07 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631896, encodeId=b4ba1631896d5, content=<a href='/topic/show?id=bd782682e3a' target=_blank style='color:#2F92EE;'>#供体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26827, encryptionId=bd782682e3a, topicName=供体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ed21829086, createdName=feather85, createdTime=Thu Jun 30 18:48:07 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998017, encodeId=ba7c199801ea9, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Thu Jan 06 11:48:07 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302392, encodeId=f922130239239, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Wed Aug 04 12:48:07 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602917, encodeId=7aa3160291e91, content=<a href='/topic/show?id=e0ee180038f' target=_blank style='color:#2F92EE;'>#T淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18003, encryptionId=e0ee180038f, topicName=T淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af0c18977520, createdName=zhenjiu129, createdTime=Wed Aug 04 12:48:07 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623400, encodeId=de111623400f3, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Wed Aug 04 12:48:07 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626746, encodeId=931e1626e46d6, content=<a href='/topic/show?id=2b104e82656' target=_blank style='color:#2F92EE;'>#嵌合抗原受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47826, encryptionId=2b104e82656, topicName=嵌合抗原受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77a421060517, createdName=dangious, createdTime=Wed Aug 04 12:48:07 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004989, encodeId=ce2210049895c, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Aug 03 22:11:11 CST 2021, time=2021-08-03, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1967941, encodeId=e941196e9415e, content=<a href='/topic/show?id=6e301800534' target=_blank style='color:#2F92EE;'>#T淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18005, encryptionId=6e301800534, topicName=T淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Thu Jun 16 16:48:07 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866177, encodeId=0e4418661e7d7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Mar 02 04:48:07 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743714, encodeId=027e1e43714c0, content=<a href='/topic/show?id=746a4e829ed' target=_blank style='color:#2F92EE;'>#嵌合抗原受体T细胞治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47829, encryptionId=746a4e829ed, topicName=嵌合抗原受体T细胞治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3baf35196076, createdName=yyanpro@33cn.c, createdTime=Wed Aug 18 01:48:07 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631896, encodeId=b4ba1631896d5, content=<a href='/topic/show?id=bd782682e3a' target=_blank style='color:#2F92EE;'>#供体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26827, encryptionId=bd782682e3a, topicName=供体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ed21829086, createdName=feather85, createdTime=Thu Jun 30 18:48:07 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998017, encodeId=ba7c199801ea9, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Thu Jan 06 11:48:07 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302392, encodeId=f922130239239, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Wed Aug 04 12:48:07 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602917, encodeId=7aa3160291e91, content=<a href='/topic/show?id=e0ee180038f' target=_blank style='color:#2F92EE;'>#T淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18003, encryptionId=e0ee180038f, topicName=T淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af0c18977520, createdName=zhenjiu129, createdTime=Wed Aug 04 12:48:07 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623400, encodeId=de111623400f3, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Wed Aug 04 12:48:07 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626746, encodeId=931e1626e46d6, content=<a href='/topic/show?id=2b104e82656' target=_blank style='color:#2F92EE;'>#嵌合抗原受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47826, encryptionId=2b104e82656, topicName=嵌合抗原受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77a421060517, createdName=dangious, createdTime=Wed Aug 04 12:48:07 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004989, encodeId=ce2210049895c, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Aug 03 22:11:11 CST 2021, time=2021-08-03, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1967941, encodeId=e941196e9415e, content=<a href='/topic/show?id=6e301800534' target=_blank style='color:#2F92EE;'>#T淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18005, encryptionId=6e301800534, topicName=T淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Thu Jun 16 16:48:07 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866177, encodeId=0e4418661e7d7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Mar 02 04:48:07 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743714, encodeId=027e1e43714c0, content=<a href='/topic/show?id=746a4e829ed' target=_blank style='color:#2F92EE;'>#嵌合抗原受体T细胞治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47829, encryptionId=746a4e829ed, topicName=嵌合抗原受体T细胞治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3baf35196076, createdName=yyanpro@33cn.c, createdTime=Wed Aug 18 01:48:07 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631896, encodeId=b4ba1631896d5, content=<a href='/topic/show?id=bd782682e3a' target=_blank style='color:#2F92EE;'>#供体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26827, encryptionId=bd782682e3a, topicName=供体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ed21829086, createdName=feather85, createdTime=Thu Jun 30 18:48:07 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998017, encodeId=ba7c199801ea9, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Thu Jan 06 11:48:07 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302392, encodeId=f922130239239, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Wed Aug 04 12:48:07 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602917, encodeId=7aa3160291e91, content=<a href='/topic/show?id=e0ee180038f' target=_blank style='color:#2F92EE;'>#T淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18003, encryptionId=e0ee180038f, topicName=T淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af0c18977520, createdName=zhenjiu129, createdTime=Wed Aug 04 12:48:07 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623400, encodeId=de111623400f3, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Wed Aug 04 12:48:07 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626746, encodeId=931e1626e46d6, content=<a href='/topic/show?id=2b104e82656' target=_blank style='color:#2F92EE;'>#嵌合抗原受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47826, encryptionId=2b104e82656, topicName=嵌合抗原受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77a421060517, createdName=dangious, createdTime=Wed Aug 04 12:48:07 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004989, encodeId=ce2210049895c, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Aug 03 22:11:11 CST 2021, time=2021-08-03, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1967941, encodeId=e941196e9415e, content=<a href='/topic/show?id=6e301800534' target=_blank style='color:#2F92EE;'>#T淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18005, encryptionId=6e301800534, topicName=T淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Thu Jun 16 16:48:07 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866177, encodeId=0e4418661e7d7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Mar 02 04:48:07 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743714, encodeId=027e1e43714c0, content=<a href='/topic/show?id=746a4e829ed' target=_blank style='color:#2F92EE;'>#嵌合抗原受体T细胞治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47829, encryptionId=746a4e829ed, topicName=嵌合抗原受体T细胞治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3baf35196076, createdName=yyanpro@33cn.c, createdTime=Wed Aug 18 01:48:07 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631896, encodeId=b4ba1631896d5, content=<a href='/topic/show?id=bd782682e3a' target=_blank style='color:#2F92EE;'>#供体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26827, encryptionId=bd782682e3a, topicName=供体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ed21829086, createdName=feather85, createdTime=Thu Jun 30 18:48:07 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998017, encodeId=ba7c199801ea9, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Thu Jan 06 11:48:07 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302392, encodeId=f922130239239, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Wed Aug 04 12:48:07 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602917, encodeId=7aa3160291e91, content=<a href='/topic/show?id=e0ee180038f' target=_blank style='color:#2F92EE;'>#T淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18003, encryptionId=e0ee180038f, topicName=T淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af0c18977520, createdName=zhenjiu129, createdTime=Wed Aug 04 12:48:07 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623400, encodeId=de111623400f3, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Wed Aug 04 12:48:07 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626746, encodeId=931e1626e46d6, content=<a href='/topic/show?id=2b104e82656' target=_blank style='color:#2F92EE;'>#嵌合抗原受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47826, encryptionId=2b104e82656, topicName=嵌合抗原受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77a421060517, createdName=dangious, createdTime=Wed Aug 04 12:48:07 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004989, encodeId=ce2210049895c, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Aug 03 22:11:11 CST 2021, time=2021-08-03, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1967941, encodeId=e941196e9415e, content=<a href='/topic/show?id=6e301800534' target=_blank style='color:#2F92EE;'>#T淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18005, encryptionId=6e301800534, topicName=T淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Thu Jun 16 16:48:07 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866177, encodeId=0e4418661e7d7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Mar 02 04:48:07 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743714, encodeId=027e1e43714c0, content=<a href='/topic/show?id=746a4e829ed' target=_blank style='color:#2F92EE;'>#嵌合抗原受体T细胞治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47829, encryptionId=746a4e829ed, topicName=嵌合抗原受体T细胞治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3baf35196076, createdName=yyanpro@33cn.c, createdTime=Wed Aug 18 01:48:07 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631896, encodeId=b4ba1631896d5, content=<a href='/topic/show?id=bd782682e3a' target=_blank style='color:#2F92EE;'>#供体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26827, encryptionId=bd782682e3a, topicName=供体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ed21829086, createdName=feather85, createdTime=Thu Jun 30 18:48:07 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998017, encodeId=ba7c199801ea9, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Thu Jan 06 11:48:07 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302392, encodeId=f922130239239, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Wed Aug 04 12:48:07 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602917, encodeId=7aa3160291e91, content=<a href='/topic/show?id=e0ee180038f' target=_blank style='color:#2F92EE;'>#T淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18003, encryptionId=e0ee180038f, topicName=T淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af0c18977520, createdName=zhenjiu129, createdTime=Wed Aug 04 12:48:07 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623400, encodeId=de111623400f3, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Wed Aug 04 12:48:07 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626746, encodeId=931e1626e46d6, content=<a href='/topic/show?id=2b104e82656' target=_blank style='color:#2F92EE;'>#嵌合抗原受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47826, encryptionId=2b104e82656, topicName=嵌合抗原受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77a421060517, createdName=dangious, createdTime=Wed Aug 04 12:48:07 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004989, encodeId=ce2210049895c, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Aug 03 22:11:11 CST 2021, time=2021-08-03, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1967941, encodeId=e941196e9415e, content=<a href='/topic/show?id=6e301800534' target=_blank style='color:#2F92EE;'>#T淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18005, encryptionId=6e301800534, topicName=T淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Thu Jun 16 16:48:07 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866177, encodeId=0e4418661e7d7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Mar 02 04:48:07 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743714, encodeId=027e1e43714c0, content=<a href='/topic/show?id=746a4e829ed' target=_blank style='color:#2F92EE;'>#嵌合抗原受体T细胞治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47829, encryptionId=746a4e829ed, topicName=嵌合抗原受体T细胞治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3baf35196076, createdName=yyanpro@33cn.c, createdTime=Wed Aug 18 01:48:07 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631896, encodeId=b4ba1631896d5, content=<a href='/topic/show?id=bd782682e3a' target=_blank style='color:#2F92EE;'>#供体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26827, encryptionId=bd782682e3a, topicName=供体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ed21829086, createdName=feather85, createdTime=Thu Jun 30 18:48:07 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998017, encodeId=ba7c199801ea9, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Thu Jan 06 11:48:07 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302392, encodeId=f922130239239, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Wed Aug 04 12:48:07 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602917, encodeId=7aa3160291e91, content=<a href='/topic/show?id=e0ee180038f' target=_blank style='color:#2F92EE;'>#T淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18003, encryptionId=e0ee180038f, topicName=T淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af0c18977520, createdName=zhenjiu129, createdTime=Wed Aug 04 12:48:07 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623400, encodeId=de111623400f3, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Wed Aug 04 12:48:07 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626746, encodeId=931e1626e46d6, content=<a href='/topic/show?id=2b104e82656' target=_blank style='color:#2F92EE;'>#嵌合抗原受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47826, encryptionId=2b104e82656, topicName=嵌合抗原受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77a421060517, createdName=dangious, createdTime=Wed Aug 04 12:48:07 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004989, encodeId=ce2210049895c, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Aug 03 22:11:11 CST 2021, time=2021-08-03, status=1, ipAttribution=)]
    2021-08-03 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

相关资讯

Blood:嵌合抗原受体T细胞疗法的临床效果、管理和神经毒性

中心点:CAR T细胞治疗后的神经毒性 与细胞因子释放综合征相关,血清炎症标志物水平与严重程度相关。3-4级神经毒性是总体存活率的负性预后因素,类固醇短暂治疗不能改变预后。摘要:嵌合抗原受体(CAR)T细胞疗法已成为一类有望用于难治性恶性肿瘤的以细胞为基础的免疫疗法。神经毒性是CAR T细胞疗法的常见的可能会危及生命的副作用,限制了CAR T细胞疗法的临床应用。Philipp Karschnia等